High sensitivity proteomics of prostate cancer tissue microarrays to discriminate between healthy and cancerous tissue

Lilla Turiák, Oliver Ozohanics, Gábor Tóth, András Ács, Ágnes Révész, K. Vékey, András Telekes, L. Drahos

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Biopsies, in the form of tissue microarrays (TMAs) were studied to identify anomalies indicative of prostate cancer at the proteome level. TMAs offer a valuable source of well-characterized biological material. However, because of the small tissue sample size method development was essential to provide the sensitivity and reliability necessary for the analysis. Surface digestion of TMA cores was followed by peptide extraction and shotgun proteomics analysis. About 5 times better sensitivity was achieved by the optimized surface digestion compared to bulk digestion of the same TMA spot and it allowed the identification of over 500 proteins from individual prostate TMA cores. Label-free quantitation showed that biological variability among all samples was about 3 times larger than the technical reproducibility. We have identified 189 proteins which showed statistically significant changes (t-test p-value <.05) in abundance between healthy and cancerous tissue samples. The proteomic profile changed according to cancer grade, but did not show a correlation with cancer stage. Results of this pilot study were further evaluated using bioinformatics tools, identifying various protein pathways affected by prostate cancer progression indicating the usefulness of studying TMA cores to identify quantitative changes in tissue proteomics. Significance: Detailed proteomics analysis of TMAs presents a good alternative for tissue analysis. Here we present a novel method, based on tissue surface digestion and nano-LC-MS measurements, which is capable of identifying and quantifying over 500 proteins from a 1.5 mm diameter tissue section. We compared healthy and cancerous prostate tissue samples, and tissues with various grades and stages of cancer. Tissue proteomics clearly distinguished healthy and cancerous samples, furthermore the results correlated well with cancer grade, but not with cancer stage. Over 100 proteins showed statistically significant abundance changes (t-test p-value <.05) between various groups. This was sufficient for a meaningful bioinformatics evaluation; showing e.g. increased abundance of proteins in cancer in the KEGG ribosome pathway, GO mRNA splicing via spliceosome, and chromatin assembly biological processes. The results highlight the feasibility of the developed method for future large-scale tissue proteomics studies using commercially available TMAs.

Original languageEnglish
JournalJournal of Proteomics
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Microarrays
Proteomics
Prostatic Neoplasms
Tissue
Digestion
Neoplasms
Proteins
Computational Biology
Bioinformatics
Prostate
Tissue Array Analysis
Spliceosomes
Biological Phenomena
Chromatin Assembly and Disassembly
Firearms
Biopsy
Proteome
Ribosomes
Sample Size

Keywords

  • Label-free quantitation
  • Mass spectrometry
  • Prostate cancer
  • Proteomics
  • Surface digestion
  • Tissue microarray

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry

Cite this

High sensitivity proteomics of prostate cancer tissue microarrays to discriminate between healthy and cancerous tissue. / Turiák, Lilla; Ozohanics, Oliver; Tóth, Gábor; Ács, András; Révész, Ágnes; Vékey, K.; Telekes, András; Drahos, L.

In: Journal of Proteomics, 01.01.2018.

Research output: Contribution to journalArticle

Turiák, Lilla ; Ozohanics, Oliver ; Tóth, Gábor ; Ács, András ; Révész, Ágnes ; Vékey, K. ; Telekes, András ; Drahos, L. / High sensitivity proteomics of prostate cancer tissue microarrays to discriminate between healthy and cancerous tissue. In: Journal of Proteomics. 2018.
@article{5265a219a80043128fd880cb2f298749,
title = "High sensitivity proteomics of prostate cancer tissue microarrays to discriminate between healthy and cancerous tissue",
abstract = "Biopsies, in the form of tissue microarrays (TMAs) were studied to identify anomalies indicative of prostate cancer at the proteome level. TMAs offer a valuable source of well-characterized biological material. However, because of the small tissue sample size method development was essential to provide the sensitivity and reliability necessary for the analysis. Surface digestion of TMA cores was followed by peptide extraction and shotgun proteomics analysis. About 5 times better sensitivity was achieved by the optimized surface digestion compared to bulk digestion of the same TMA spot and it allowed the identification of over 500 proteins from individual prostate TMA cores. Label-free quantitation showed that biological variability among all samples was about 3 times larger than the technical reproducibility. We have identified 189 proteins which showed statistically significant changes (t-test p-value <.05) in abundance between healthy and cancerous tissue samples. The proteomic profile changed according to cancer grade, but did not show a correlation with cancer stage. Results of this pilot study were further evaluated using bioinformatics tools, identifying various protein pathways affected by prostate cancer progression indicating the usefulness of studying TMA cores to identify quantitative changes in tissue proteomics. Significance: Detailed proteomics analysis of TMAs presents a good alternative for tissue analysis. Here we present a novel method, based on tissue surface digestion and nano-LC-MS measurements, which is capable of identifying and quantifying over 500 proteins from a 1.5 mm diameter tissue section. We compared healthy and cancerous prostate tissue samples, and tissues with various grades and stages of cancer. Tissue proteomics clearly distinguished healthy and cancerous samples, furthermore the results correlated well with cancer grade, but not with cancer stage. Over 100 proteins showed statistically significant abundance changes (t-test p-value <.05) between various groups. This was sufficient for a meaningful bioinformatics evaluation; showing e.g. increased abundance of proteins in cancer in the KEGG ribosome pathway, GO mRNA splicing via spliceosome, and chromatin assembly biological processes. The results highlight the feasibility of the developed method for future large-scale tissue proteomics studies using commercially available TMAs.",
keywords = "Label-free quantitation, Mass spectrometry, Prostate cancer, Proteomics, Surface digestion, Tissue microarray",
author = "Lilla Turi{\'a}k and Oliver Ozohanics and G{\'a}bor T{\'o}th and Andr{\'a}s {\'A}cs and {\'A}gnes R{\'e}v{\'e}sz and K. V{\'e}key and Andr{\'a}s Telekes and L. Drahos",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jprot.2018.11.009",
language = "English",
journal = "Journal of Proteomics",
issn = "1874-3919",
publisher = "Elsevier",

}

TY - JOUR

T1 - High sensitivity proteomics of prostate cancer tissue microarrays to discriminate between healthy and cancerous tissue

AU - Turiák, Lilla

AU - Ozohanics, Oliver

AU - Tóth, Gábor

AU - Ács, András

AU - Révész, Ágnes

AU - Vékey, K.

AU - Telekes, András

AU - Drahos, L.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Biopsies, in the form of tissue microarrays (TMAs) were studied to identify anomalies indicative of prostate cancer at the proteome level. TMAs offer a valuable source of well-characterized biological material. However, because of the small tissue sample size method development was essential to provide the sensitivity and reliability necessary for the analysis. Surface digestion of TMA cores was followed by peptide extraction and shotgun proteomics analysis. About 5 times better sensitivity was achieved by the optimized surface digestion compared to bulk digestion of the same TMA spot and it allowed the identification of over 500 proteins from individual prostate TMA cores. Label-free quantitation showed that biological variability among all samples was about 3 times larger than the technical reproducibility. We have identified 189 proteins which showed statistically significant changes (t-test p-value <.05) in abundance between healthy and cancerous tissue samples. The proteomic profile changed according to cancer grade, but did not show a correlation with cancer stage. Results of this pilot study were further evaluated using bioinformatics tools, identifying various protein pathways affected by prostate cancer progression indicating the usefulness of studying TMA cores to identify quantitative changes in tissue proteomics. Significance: Detailed proteomics analysis of TMAs presents a good alternative for tissue analysis. Here we present a novel method, based on tissue surface digestion and nano-LC-MS measurements, which is capable of identifying and quantifying over 500 proteins from a 1.5 mm diameter tissue section. We compared healthy and cancerous prostate tissue samples, and tissues with various grades and stages of cancer. Tissue proteomics clearly distinguished healthy and cancerous samples, furthermore the results correlated well with cancer grade, but not with cancer stage. Over 100 proteins showed statistically significant abundance changes (t-test p-value <.05) between various groups. This was sufficient for a meaningful bioinformatics evaluation; showing e.g. increased abundance of proteins in cancer in the KEGG ribosome pathway, GO mRNA splicing via spliceosome, and chromatin assembly biological processes. The results highlight the feasibility of the developed method for future large-scale tissue proteomics studies using commercially available TMAs.

AB - Biopsies, in the form of tissue microarrays (TMAs) were studied to identify anomalies indicative of prostate cancer at the proteome level. TMAs offer a valuable source of well-characterized biological material. However, because of the small tissue sample size method development was essential to provide the sensitivity and reliability necessary for the analysis. Surface digestion of TMA cores was followed by peptide extraction and shotgun proteomics analysis. About 5 times better sensitivity was achieved by the optimized surface digestion compared to bulk digestion of the same TMA spot and it allowed the identification of over 500 proteins from individual prostate TMA cores. Label-free quantitation showed that biological variability among all samples was about 3 times larger than the technical reproducibility. We have identified 189 proteins which showed statistically significant changes (t-test p-value <.05) in abundance between healthy and cancerous tissue samples. The proteomic profile changed according to cancer grade, but did not show a correlation with cancer stage. Results of this pilot study were further evaluated using bioinformatics tools, identifying various protein pathways affected by prostate cancer progression indicating the usefulness of studying TMA cores to identify quantitative changes in tissue proteomics. Significance: Detailed proteomics analysis of TMAs presents a good alternative for tissue analysis. Here we present a novel method, based on tissue surface digestion and nano-LC-MS measurements, which is capable of identifying and quantifying over 500 proteins from a 1.5 mm diameter tissue section. We compared healthy and cancerous prostate tissue samples, and tissues with various grades and stages of cancer. Tissue proteomics clearly distinguished healthy and cancerous samples, furthermore the results correlated well with cancer grade, but not with cancer stage. Over 100 proteins showed statistically significant abundance changes (t-test p-value <.05) between various groups. This was sufficient for a meaningful bioinformatics evaluation; showing e.g. increased abundance of proteins in cancer in the KEGG ribosome pathway, GO mRNA splicing via spliceosome, and chromatin assembly biological processes. The results highlight the feasibility of the developed method for future large-scale tissue proteomics studies using commercially available TMAs.

KW - Label-free quantitation

KW - Mass spectrometry

KW - Prostate cancer

KW - Proteomics

KW - Surface digestion

KW - Tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=85056634029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056634029&partnerID=8YFLogxK

U2 - 10.1016/j.jprot.2018.11.009

DO - 10.1016/j.jprot.2018.11.009

M3 - Article

JO - Journal of Proteomics

JF - Journal of Proteomics

SN - 1874-3919

ER -